Psychedelics

Net Cash Used in Operating Activities of $24.2 million USD for year ended December 31, 2020 Mind Medicine Inc. a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31 2020. 2020 Financial Highlights Total assets as of December 31, 2020 were $85.6 million including $80.1 million in cash Net Cash Used in Operating Activities of $24.2 million for ...

Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ( $30.5 million CAD) for year ended December 31, 2020

Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its annual 2020 financial results for the year ended December 31 2020.

2020 Financial Highlights (in USD)

  • Total assets as of December 31, 2020 were $85.6 million , including $80.1 million in cash
  • Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million for the year ended December 31, 2020 .
  • Net and comprehensive loss of $35.1 million for the year ended December 31, 2020 .

Current Cash Balance
As of March 30, 2021 maintains a current cash balance of $161 million USD ( $203 million CAD) to advance its portfolio and build out it's technology division.

Earnings Call
An earnings call will be held Thursday, April 1, 2021 at 10:00 am ET .  Details are below:
https://mindmed-co.zoom.us/webinar/register/WN_2-RxTijCTzOX2cpuaMrXJw

Complete financial statements along with related management's discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com .

About MindMed
MindMed is a psychedelic medicine biotech company seeking to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness. The Company is assembling a drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC.

MindMed trades on the Canadian exchange NEO under the symbol MMED . MindMed is also traded in the United States under the symbol MMEDF and in Germany under the symbol MMQ .

MindMed Forward-Looking Statements
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "will", "may", "should", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe", "potential" or "continue", or the negative thereof or similar variations. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described under the heading "Risk Factors" in the Company's annual information form for the year ended December 31, 2020 filed with the securities regulatory authorities in all provinces and territories of Canada and available under the Company's profile on SEDAR at www.sedar.com . Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

Media Contact: mindmed@150bond.com

Cision View original content: http://www.prnewswire.com/news-releases/mindmed-announces-2020-year-end-financial-results-current-cash-balance-of-161-million-usd-203-million-cad-to-support-drug-development-pipeline-and-creation-of-psychedelic-medicine-tech-platform-301258180.html

SOURCE Mind Medicine (MindMed) Inc.

Cision View original content: http://www.newswire.ca/en/releases/archive/March2021/30/c5156.html

News Provided by Canada Newswire via QuoteMedia

Psychedelics Company Silo Wellness Announces U.S. DTC Eligibility

Psychedelics Company Silo Wellness Announces U.S. DTC Eligibility

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.

DTC is a subsidiary of The Depository Trust & Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly-traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a wider selection of brokerage firms.

Keep reading... Show less

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION), covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregation in Parkinson's disease (PD).

Keep reading... Show less
Awakn Life Sciences to Participate at Upcoming December Conferences

Awakn Life Sciences to Participate at Upcoming December Conferences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, Chief Executive Officer, is scheduled to present at the following upcoming virtual December investor conferences.

H.C. Wainwright 2nd Annual Psychedelics Conference
Presentation: On Demand Beginning Monday, December 6th at 7:00 a.m. ET
Registration: Click here

Keep reading... Show less

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

London, UK - 3 December 2021

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Michael Falvey as Chief Financial Officer, replacing Piers Morgan when he leaves the company, as previously announced, at the end of the year.

Keep reading... Show less
Gwella logo

Gwella Mushrooms: Alternative Wellness Platform for Functional Health, Mushrooms and Psychedelics

Gwella focuses on building an accessible, original and scalable over-the-counter portfolio of functional and psychedelic mushroom products that enhance individual and community wellness. The company's advanced direct-to-consumer platform combines an innovative mix of wellness, mushrooms and psychedelics with a modern twist in an integration of media and technology.

Gwella Wellness is the company's purpose-built consumer product vertical. Using exclusive ingredients, formulations, delivery systems, testing and research, Gwella Branded CPG tackles health and wellness through high volume avenues in retail, e-commerce and clinical, retreat and legal jurisdictions. Its product pipeline includes Gwella's flagship Mojo, Journey, and incoming MYMYCO, Yugen and Anxiety Strips, with more products in development.

Keep reading... Show less
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference

NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference

NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference, being held virtually on Monday, December 6, 2021

H.C. Wainwright 2nd Annual Psychedelics Virtual Conference Details:

Keep reading... Show less

Top News

Related News